Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Biological and small molecule strategies in migraine therapy with relation to the calcitonin gene-related peptide family of peptides

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Exercise training as prophylactic strategy in the management of neutropenia during chemotherapy

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Advances in migraine and headache therapy (BJP 75th anniversary)

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  3. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Metabolic control and sex: A focus on inflammatory-linked mediators

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Myocardial perfusion recovery induced by an α-calcitonin gene-related peptide analogue

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Could Experimental Inflammation Provide Better Understanding of Migraines?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Identifying molecular targets in trigeminal nociception

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Repair-related molecular changes during recovery phase of ischemic stroke in female rats

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Migraine is one of the most common of neurological disorders with a global prevalence of up to 15%. One in five migraineurs have frequent episodic or chronic migraine requiring prophylactic treatment. In recent years, specific pharmacological treatments targeting calcitonin gene-related peptide (CGRP) signalling molecules have provided safe and effective treatments, monoclonal antibodies for prophylaxis and gepants for acute therapy. Albeit beneficial, it is important to understand the molecular mechanisms of these new drugs to better understand migraine pathophysiology and improve therapy. Here, we describe current views on the role of the CGRP family of peptides - CGRP, calcitonin, adrenomedullin, amylin - and their receptors in the trigeminovascular system. All these molecules are present within the trigeminovascular system but differ in expression and localization. It is likely that they have different roles, which can be utilized in providing additional drug targets. LINKED ARTICLES: This article is part of a themed issue on Advances in Migraine and Headache Therapy (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.3/issuetoc.

OriginalsprogEngelsk
TidsskriftBritish Journal of Pharmacology
Vol/bind179
Udgave nummer3
Sider (fra-til)371-380
Antal sider10
ISSN0007-1188
DOI
StatusUdgivet - feb. 2022

ID: 67198162